Increased transparency in IARC Monograph programme

Lancet Oncology

Volumn 6, Issue 10, 2005, Pages 735-

  Collingridge, David ^a  

^a THE LANCET   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE;

ACCESS TO INFORMATION; CANCER RESEARCH; CANCER RISK; CARCINOGENICITY; CHEMICAL CARCINOGENESIS; COMPETENCE; HEALTH CARE ORGANIZATION; HUMAN; INFORMATION DISSEMINATION; INTERNATIONAL COOPERATION; MEDICAL LITERATURE; MEDICAL SPECIALIST; NOTE; PRIORITY JOURNAL; PUBLIC HEALTH; PUBLICATION;

EID: 26444615186     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)70364-8     Document Type: Letter

References (10)

1. A Burton Is industry influencing IARC to downgrade carcinogens? Lancet Oncol 4 2003 4
2. Editorial. Transparency at IARC Lancet 361 2003 189
3. A Burton Will IARC election help to change "name security" policy? Lancet Oncol 4 2003 262
4. D Collingridge What does IARC have to lose? Lancet Oncol 4 2003 333
5. V Cogliano Y Grosse R Baan et al. Advice on formaldehyde and glycol ethers Lancet Oncol 5 2004 528
6. S Shapiro Oral oestrogen-progestagen contraceptive, menopausal treatment, and cancer Lancet Oncol 6 2005 736
7. V Cogliano Y Grosse R Baan et al. Author's reply Lancet Oncol 6 2005 737
8. A James R Horton D Collingridge et al. The Lancet's policy on conflicts of interest-2004 Lancet 363 2004 2-3
9. V Cogliano R Baan K Straif et al. Transparency in the IARC Monograph Lancet Oncol 6 2005 747
10. A Szarewski Oral oestrogen-progestagen contraceptive, menopausal treatment, and cancer Lancet Oncol 6 2005 736